Authors:
Harpole, DH
Moore, MB
Herndon, JE
Aloia, T
D'Amico, TA
Sporn, T
Parr, A
Linoila, I
Allegra, C
Citation: Dh. Harpole et al., The prognostic value of molecular marker analysis in patients treated withtrimodality therapy for esophageal cancer, CLIN CANC R, 7(3), 2001, pp. 562-569
Authors:
Harris, LN
Liotcheva, V
Broadwater, G
Ramirez, MJ
Maimonis, P
Anderson, S
Everett, T
Harpole, D
Moore, MB
Berry, DA
Rizzeri, D
Vredenburgh, JJ
Bentley, RC
Citation: Ln. Harris et al., Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy, J CL ONCOL, 19(6), 2001, pp. 1698-1706
Authors:
Marom, EM
Aloia, TA
Moore, MB
Hara, M
Herndon, JE
Harpole, DH
Goodman, PC
Patz, EF
Citation: Em. Marom et al., Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer, LUNG CANC, 33(2-3), 2001, pp. 99-107
Authors:
Kawakami, K
Brabender, J
Lord, RV
Groshen, S
Greenwald, BD
Krasna, MJ
Yin, J
Fleisher, AS
Abraham, JM
Beer, DG
Sidransky, D
Huss, HT
Demeester, TR
Eads, C
Laird, PW
Ilson, DH
Kelsen, DP
Harpole, D
Moore, MB
Danenberg, KD
Danenberg, PV
Meltzer, SJ
Citation: K. Kawakami et al., Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma, J NAT CANC, 92(22), 2000, pp. 1805-1811
Authors:
D'Amico, TA
Massey, M
Herndon, JE
Moore, MB
Harpole, DH
Citation: Ta. D'Amico et al., A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers, J THOR SURG, 117(4), 1999, pp. 736-742